Medical Pharmacology: Coronary Vasodilators

Medical Pharmacology Chapter 9: Coronary Artery Disease Practice Questions Practice Questions

Agents which may promote coronary vasodilation:
1. beta-blockers
2. calcium channel blockers
3. both
4. neither
Nitric oxide: homeostatic activities:
1. cardiovascular tone
2. platelet regulation
3. gastrointestinal smooth muscle contraction
4. A & B
5. A, B & C
Nitric oxide: precursor amino acid
1. tyrosine
2. tryptophan
3. arginine
4. proline
5. phenylalanine
Nitric oxide half-life:
1. < 5 seconds
2. thirty seconds
3. one-minute
4. thirty minutes
5. > one-hour
Nitric oxide mainly inactivated by:
1. NO synthase
2. reuptake
3. interaction with hemoglobin
4. monoamine oxidase
5. catechol-O-methyltransferase
Cardiovascular system: nitric oxide effects
1. continual NO release associated with flow-induced shear stress
2. intermittent NO release associated with pulsatile arterial flow
3. significant determinant of pulmonary distribution of cardiac output
4. A & C
5. A, B & C
Decreased oxygenation and nitric oxide response:
1. increased NO production
2. decreased NO production
3. no effect on NO production
Comparing arteries and veins: nitric oxide production
1. veins produce more
2. arteries produce more
3. equal
Nitric oxide and platelet aggregation and adhesion:
1. nitric oxide inhibits platelet aggregation and adhesion
2. nitric oxide promotes platelet aggregation and adhesion
3. no effect
Probable site where NO acts as a neurotransmitter:
1. neuromuscular junction
2. innervation of the corpora cavernosa
3. basal ganglia
4. Renshaw cell
Involvement of nitric oxide and immune function:
1. suppression of macrophage activation by cytokines
2. modulation of inflammation
3. both
4. neither
Clinical uses of nitric oxide
1. management of pulmonary hypertension newborn
2. adult respiratory distress syndrome
3. management of pulmonary hypertension following cardiopulmonary bypass
4. B & C
5. A, B & C